Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionised treatment of advanced non-small cell lung cancer (aNSCLC), but a proportion of patients had no clinical benefit and even experienced detrimental effects. This study aims to characterise patients experiencing hyperprogression (HPD) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zulato, Elisabetta, Del Bianco, Paola, Nardo, Giorgia, Attili, Ilaria, Pavan, Alberto, Boscolo Bragadin, Andrea, Marra, Ludovica, Pasello, Giulia, Fassan, Matteo, Calabrese, Fiorella, Guarneri, Valentina, Conte, Pier Franco, Indraccolo, Stefano, Bonanno, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681746/
https://www.ncbi.nlm.nih.gov/pubmed/36175621
http://dx.doi.org/10.1038/s41416-022-01978-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681746/
https://www.ncbi.nlm.nih.gov/pubmed/36175621
http://dx.doi.org/10.1038/s41416-022-01978-1

Ejemplares similares